Details for New Drug Application (NDA): 018144
✉ Email this page to a colleague
NDA 018144 describes CENTRAX, which is a drug marketed by Parke Davis and is included in two NDAs. Additional details are available on the CENTRAX profile page.
The generic ingredient in CENTRAX is prazepam. There are four drug master file entries for this compound. Additional details are available on the prazepam profile page.
The generic ingredient in CENTRAX is prazepam. There are four drug master file entries for this compound. Additional details are available on the prazepam profile page.
Summary for 018144
| Tradename: | CENTRAX |
| Applicant: | Parke Davis |
| Ingredient: | prazepam |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 018144
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 20MG | ||||
| Approval Date: | May 10, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
